ClinicalTrials.Veeva

Find clinical trials for Multiple Myeloma in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Cleveland, OH, USA:

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen
Janssen

Cleveland, Ohio, United States and 211 other locations

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9)

doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab

Phase 2

Pfizer
Pfizer

Cleveland, Ohio, United States and 41 other locations

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

Phase 2

Celgene
Celgene

Cleveland, Ohio, United States and 48 other locations

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Phase 3

Pfizer
Pfizer

Cleveland, Ohio, United States and 210 other locations

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage)

of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...

Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: CB-011

Phase 1

Caribou Biosciences

Cleveland, Ohio, United States and 17 other locations

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.Phase 2: To determine the overall response rat ...

Active, not recruiting
Multiple Myeloma
Drug: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone

Phase 1, Phase 2

Celgene
Celgene

Cleveland, Ohio, United States and 1 other location

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combin ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: CC-220

Phase 1, Phase 2

Celgene
Celgene

Cleveland, Ohio, United States and 88 other locations

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy an...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab IV

Phase 3

Janssen
Janssen

Cleveland, Ohio, United States and 164 other locations

Locations recently updated

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Iberdomide

Phase 3

Celgene
Celgene

Cleveland, Ohio, United States and 256 other locations

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

in combination with IMiDs® immunomodulatory drugs in patients with multiple myeloma. As a result, enrollment into this study has be...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

Phase 1

Celgene
Celgene

Cleveland, Ohio, United States and 21 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems